Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial.

Abstract

In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.

Mature Results of a Phase II Trial of Concomitant Cisplatin/Pelvic Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervix

“…Our late morbidity rate (10%) is comparable to those reported in other studies patients completed chemotherapy according to protocol. The late morbidity rate in this study was 12% (7/60), 2 of which [2,12,21,35].…”

“…No treatment-related deaths occurred. Conclusion: Con-pared with patients treated by pelvic radiation alone, most comitant CDDP/RT is a safe and tolerable method of treating centers have not accepted it as the standard of care [10][11][12]. patients with locally advanced squamous cell carcinoma of the Concomitant radiation/hydroxyurea has, however, become a cervix.…”

The current management of cervical cancer

“…26,27 The combination of cisplatin and 5-fluorouracil has also been used as concurrent chemotherapy. They are both radiosensitisers and are associated with reduced disease progression and a longer period of disease remission.…”

“…With a central recurrence, exenterative surgery in carefully selected women could give a 5-year survival of 40-60%. 27,30 If there is recurrence after surgery, the usual treatment is radiotherapy with or without platinum-based chemotherapy. The role of chemotherapy is mainly for palliation to relieve symptoms as well as to prolong survival.…”

A survey on staging and treatment in uterine cervical carcinoma in the Radiotherapy Cooperative Group of the European Organization for Research and Treatment of Cancer

“…The Radiation Therapy Oncology Group tested misonidazole as a hypoxic cell-sensitizer in a randomized trial; no improvement in survival was observed [2]. The Gynecology Oncology Group compared hydroxyurea vs. misonidazole with no improvement in survival [38].The Medical Research Council Working Party on advanced carcinoma of the cervix ran another randomized trial with Ro 03-8799 (pimonidazole) as a hypoxic cell-sensitizer. They observed no bene®t by adding pimonidazole to radiotherapy, and a truly adverse effect of the drug was a possible cause of failure in this trial [7].…”